Brookstone Capital Management Has $604,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

Brookstone Capital Management cut its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 7.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,624 shares of the medical research company’s stock after selling 211 shares during the quarter. Brookstone Capital Management’s holdings in IQVIA were worth $604,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Rise Advisors LLC acquired a new position in shares of IQVIA during the 1st quarter worth approximately $31,000. Versant Capital Management Inc grew its holdings in IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares in the last quarter. Riverview Trust Co acquired a new position in IQVIA in the 1st quarter valued at $32,000. Opal Wealth Advisors LLC acquired a new position in IQVIA in the 2nd quarter valued at $27,000. Finally, Covestor Ltd grew its holdings in IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock valued at $39,000 after buying an additional 48 shares in the last quarter. 89.62% of the stock is owned by institutional investors and hedge funds.

IQVIA Price Performance

Shares of IQV stock opened at $243.11 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA Holdings Inc. has a twelve month low of $167.42 and a twelve month high of $261.73. The company has a market cap of $44.32 billion, a P/E ratio of 33.21, a P/E/G ratio of 2.22 and a beta of 1.49. The business has a fifty day simple moving average of $225.23 and a 200 day simple moving average of $232.36.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same period in the prior year, the company earned $2.22 EPS. IQVIA’s revenue for the quarter was up 2.3% on a year-over-year basis. On average, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.24 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have commented on IQV. The Goldman Sachs Group began coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 price objective on the stock. Argus raised IQVIA to a “strong-buy” rating in a report on Wednesday, July 31st. Truist Financial upped their price objective on IQVIA from $292.00 to $300.00 and gave the company a “buy” rating in a report on Tuesday, July 23rd. Evercore ISI upped their target price on IQVIA from $230.00 to $270.00 and gave the company an “outperform” rating in a research report on Tuesday, July 23rd. Finally, StockNews.com upgraded IQVIA from a “hold” rating to a “buy” rating in a research report on Monday. Four equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $265.67.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.